These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Ancrod infusion for anticoagulation during and after PTCA in a patient with heparin-induced thrombocytopenia. Moore JA; Burket MW; Puri S; Temesy-Armos P; Lachant N; Skeel R Cathet Cardiovasc Diagn; 1994 Jul; 32(3):286-7. PubMed ID: 7954782 [TBL] [Abstract][Full Text] [Related]
10. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis. Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465 [TBL] [Abstract][Full Text] [Related]
11. Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management. Lathan LO; Staggers SL Heart Lung; 1996; 25(6):451-60; quiz 461-2. PubMed ID: 8950124 [TBL] [Abstract][Full Text] [Related]
12. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Lubenow N; Warkentin TE; Greinacher A; Wessel A; Sloane DA; Krahn EL; Magnani HN Thromb Res; 2006; 117(5):507-15. PubMed ID: 15907979 [TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects. Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212 [TBL] [Abstract][Full Text] [Related]
14. Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid. Kanagasabay R; Unsworth-White MJ; Farnsworth G; Haxby EJ; Smith EE J Thorac Cardiovasc Surg; 2000 Aug; 120(2):428-9. PubMed ID: 10917979 [No Abstract] [Full Text] [Related]
15. Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation. Spiess BD; Gernsheimer T; Vocelka C; Chandler WL; Benak A; Joy JV; Wright I; Hofer BO J Cardiothorac Vasc Anesth; 1996 Dec; 10(7):918-21. PubMed ID: 8969402 [No Abstract] [Full Text] [Related]
16. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Jeske WP; Walenga JM Methods Mol Med; 2004; 93():61-82. PubMed ID: 14733328 [No Abstract] [Full Text] [Related]
17. Coagulation studies during therapeutic application of arvin. Vinazzer H Thromb Res; 1976 Feb; 8(2):243-8. PubMed ID: 943132 [No Abstract] [Full Text] [Related]
18. Normal activated clotting time despite adequate anticoagulation with ancrod in a patient with heparin-associated thrombocytopenia and thrombosis undergoing cardiopulmonary bypass. Spiekermann BF; Lake CL; Rich GF; Humphries JE Anesthesiology; 1994 Mar; 80(3):686-8. PubMed ID: 8141466 [No Abstract] [Full Text] [Related]
19. [Defibrination with ancrod (arvin) in peripheral arterial occlusive diseases. Principle, indications, contraindications technic and course]. Heidrich H ZFA (Stuttgart); 1978 Nov; 54(32):1648-51. PubMed ID: 735320 [No Abstract] [Full Text] [Related]
20. Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Teasdale SJ; Zulys VJ; Mycyk T; Baird RJ; Glynn MF Ann Thorac Surg; 1989 Nov; 48(5):712-3. PubMed ID: 2818066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]